Candriam S.C.A. Tg Therapeutics, Inc. Transaction History

Candriam S.C.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $2.76 Million - $7.24 Million	-353,983 Closed	0 $0
Q2 2021 Jul 20, 2021	SELL	$32.5 - $48.96 $21.3 Million - $32.1 Million	-656,244 Reduced 64.96%	353,983 $13.7 Million
Q4 2020 Jan 22, 2021	SELL	$25.27 - $54.9 $12.4 Million - $27 Million	-491,262 Reduced 32.72%	1,010,227 $52.6 Million
Q3 2020 Oct 19, 2020	SELL	$18.49 - $27.24 $842,811 - $1.24 Million	-45,582 Reduced 2.95%	1,501,489 $40.2 Million
Q2 2020 Jul 23, 2020	BUY	$8.9 - $21.84 $5.23 Million - $12.8 Million	587,098 Added 61.16%	1,547,071 $30.1 Million
Q1 2020 May 26, 2020	BUY	$7.14 - $15.99 $406 - $911	57 Added 0.01%	959,973 $10.4 Million
Q4 2019 Jan 21, 2020	BUY	$5.1 - $11.2 $4.9 Million - $10.8 Million	959,916 New	959,916 $11,000
Q3 2019 Oct 21, 2019	SELL	$5.38 - $8.99 $3.72 Million - $6.22 Million	-692,000 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$5.15 - $14.0 $1.38 Million - $3.74 Million	267,000 Added 62.82%	692,000 $3.88 Million
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $812,500 - $975,000	65,000 Added 18.06%	425,000 $5.59 Million
Q1 2018 May 09, 2018	BUY	$8.7 - $16.8 $782,999 - $1.51 Million	90,000 Added 33.33%	360,000 $5.11 Million
Q4 2017 Feb 07, 2018	BUY	$7.35 - $12.3 $367,500 - $615,000	50,000 Added 22.73%	270,000 $2.21 Million
Q3 2017 Nov 03, 2017	BUY	$10.0 - $12.7 $2.2 Million - $2.79 Million	220,000	220,000 $2.61 Million

335

88.3M

2.08M

1.51M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.48B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.